MA35208B1 - Protéines de liaison à bcma (cd269/tnfrsf17) - Google Patents
Protéines de liaison à bcma (cd269/tnfrsf17)Info
- Publication number
- MA35208B1 MA35208B1 MA36613A MA36613A MA35208B1 MA 35208 B1 MA35208 B1 MA 35208B1 MA 36613 A MA36613 A MA 36613A MA 36613 A MA36613 A MA 36613A MA 35208 B1 MA35208 B1 MA 35208B1
- Authority
- MA
- Morocco
- Prior art keywords
- binding proteins
- bcma
- tnfrsf17
- bcma binding
- antigen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
L'invention concerne des protéines de liaison à l'antigène et des fragments de celles-ci, qui se lient spécifiquement à l'antigène de maturation des lymphocytes b (bcma), en particulier le bcma humain (hbcma), et qui inhibent la liaison de baff et d'april au récepteur du bcma. L'invention concerne de plus des compositions pharmaceutiques, des procédés de criblage et des méthodes de traitement médical.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161490732P | 2011-05-27 | 2011-05-27 | |
US201261647196P | 2012-05-15 | 2012-05-15 | |
PCT/EP2012/059762 WO2012163805A1 (fr) | 2011-05-27 | 2012-05-24 | Protéines de liaison à bcma (cd269/tnfrsf17) |
Publications (1)
Publication Number | Publication Date |
---|---|
MA35208B1 true MA35208B1 (fr) | 2014-06-02 |
Family
ID=46148885
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA36613A MA35208B1 (fr) | 2011-05-27 | 2013-12-25 | Protéines de liaison à bcma (cd269/tnfrsf17) |
Country Status (37)
Country | Link |
---|---|
US (1) | US20140105915A1 (fr) |
EP (4) | EP3693394A1 (fr) |
JP (5) | JP6263467B2 (fr) |
KR (1) | KR101972446B1 (fr) |
CN (2) | CN106279418A (fr) |
AR (1) | AR086579A1 (fr) |
AU (1) | AU2012264890C1 (fr) |
BR (1) | BR112013028779B8 (fr) |
CA (1) | CA2833820C (fr) |
CL (2) | CL2013003373A1 (fr) |
CO (1) | CO6811809A2 (fr) |
CR (1) | CR20130624A (fr) |
CY (2) | CY1126300T1 (fr) |
DK (1) | DK3415531T3 (fr) |
DO (1) | DOP2013000280A (fr) |
EA (2) | EA028220B1 (fr) |
ES (1) | ES2953190T3 (fr) |
FI (2) | FI3415531T3 (fr) |
FR (1) | FR23C1032I1 (fr) |
HR (1) | HRP20231066T1 (fr) |
HU (2) | HUE063461T2 (fr) |
IL (2) | IL228784B (fr) |
LT (1) | LT3415531T (fr) |
MA (1) | MA35208B1 (fr) |
MX (1) | MX351069B (fr) |
MY (1) | MY177970A (fr) |
NL (1) | NL301241I2 (fr) |
PE (1) | PE20141045A1 (fr) |
PL (1) | PL3415531T3 (fr) |
PT (1) | PT3415531T (fr) |
RS (1) | RS64791B1 (fr) |
SG (1) | SG194176A1 (fr) |
SI (1) | SI3415531T1 (fr) |
TW (2) | TWI644924B (fr) |
UY (1) | UY34101A (fr) |
WO (1) | WO2012163805A1 (fr) |
ZA (1) | ZA201308635B (fr) |
Families Citing this family (199)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA02001665A (es) | 1999-08-17 | 2003-07-14 | Biogen Inc | Receptor de baff (bcma) como agente inmunorregulador. |
UA112434C2 (uk) | 2011-05-27 | 2016-09-12 | Ґлаксо Ґруп Лімітед | Антигензв'язувальний білок, який специфічно зв'язується з всма |
DK3415531T3 (da) * | 2011-05-27 | 2023-09-18 | Glaxo Group Ltd | Bcma (cd269/tnfrsf17)-bindende proteiner |
TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對bcma之e3以及cd3的結合分子 |
EP2836239A1 (fr) | 2012-04-11 | 2015-02-18 | The United States of America, as Represented By the Secretary, Department of Health and Human Services | Récepteurs antigéniques chimériques ciblant un antigène de maturation des lymphocytes b |
EP2914628A1 (fr) | 2012-11-01 | 2015-09-09 | Max-Delbrück-Centrum für Molekulare Medizin | Anticorps qui se lie à cd269 (bcma) pouvant être utilisé dans le traitement de maladies des cellules plasmatiques comme le myélome multiple et les maladies auto-immunes |
TW201425336A (zh) * | 2012-12-07 | 2014-07-01 | Amgen Inc | Bcma抗原結合蛋白質 |
US9243058B2 (en) | 2012-12-07 | 2016-01-26 | Amgen, Inc. | BCMA antigen binding proteins |
EP2762497A1 (fr) * | 2013-02-05 | 2014-08-06 | EngMab AG | Anticorps bispécifiques contre la CD3epsilon et BCMA |
WO2014122144A1 (fr) | 2013-02-05 | 2014-08-14 | Engmab Ag | Anticorps bispécifiques anti-cd3ɛ et bcma |
EP2762496A1 (fr) * | 2013-02-05 | 2014-08-06 | EngMab AG | Procédé pour la sélection d'anticorps contre BCMA |
JP2016507066A (ja) * | 2013-02-08 | 2016-03-07 | インスティテュート フォー ミエローマ アンド ボーン キャンサー リサーチ | 多発性骨髄腫、慢性リンパ球性白血病、およびb細胞非ホジキンリンパ腫の改善された診断方法、予後予測方法、およびモニタリング方法 |
AR095374A1 (es) * | 2013-03-15 | 2015-10-14 | Amgen Res (Munich) Gmbh | Moléculas de unión para bcma y cd3 |
GB2513405A (en) | 2013-04-26 | 2014-10-29 | Adc Biotechnology Ltd | Method of synthesising ADCs using affinity resins |
AU2014287221C1 (en) | 2013-07-09 | 2020-03-05 | Annexon, Inc. | Anti-complement factor C1q antibodies and uses thereof |
WO2015117229A1 (fr) | 2014-02-07 | 2015-08-13 | Mcmaster University | Coupleur d'antigènes des lymphocytes t trifonctionnel et méthodes et utilisations associées |
US10752665B2 (en) | 2014-02-27 | 2020-08-25 | Ucl Business Ltd | April variants |
JP2017513818A (ja) | 2014-03-15 | 2017-06-01 | ノバルティス アーゲー | キメラ抗原受容体を使用する癌の処置 |
JP6755805B2 (ja) * | 2014-04-30 | 2020-09-16 | マックス−デルブリュック−ツェントルム フューア モレキュラーレ メディツィン イン デア ヘルムホルツ−ゲマインシャフト | Cd269(bcma)に対するヒト化抗体 |
EP3828265A1 (fr) | 2014-06-06 | 2021-06-02 | Bluebird Bio, Inc. | Compositions de lymphocytes t améliorées |
MY181834A (en) * | 2014-07-21 | 2021-01-08 | Novartis Ag | Treatment of cancer using humanized anti-bcma chimeric antigen receptor |
EP3193915A1 (fr) | 2014-07-21 | 2017-07-26 | Novartis AG | Combinaisons de faibles doses renforçant l'immunité d'inhibiteurs de mtor et car |
AR101829A1 (es) | 2014-07-21 | 2017-01-18 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno cll-1 |
RU2747457C2 (ru) | 2014-07-24 | 2021-05-05 | Блубёрд Био, Инк. | Химерные антигенные рецепторы к bcma |
EP2982692A1 (fr) | 2014-08-04 | 2016-02-10 | EngMab AG | Anticorps bispécifiques contre la CD3epsilon et BCMA |
WO2016044605A1 (fr) | 2014-09-17 | 2016-03-24 | Beatty, Gregory | Ciblage de cellules cytotoxiques avec des récepteurs chimériques pour l'immunothérapie adoptive |
GB201419185D0 (en) * | 2014-10-28 | 2014-12-10 | Adc Biotechnology Ltd | Method of synthesising ADCs using affinity resin |
CA2966005C (fr) | 2014-10-31 | 2021-04-27 | Abbvie Biotherapeutics Inc. | Anticorps anti-cs1 et conjugues anticorps-medicament |
EP3023437A1 (fr) | 2014-11-20 | 2016-05-25 | EngMab AG | Anticorps bispécifiques contre la CD3epsilon et BCMA |
EP3029068A1 (fr) * | 2014-12-03 | 2016-06-08 | EngMab AG | Anticorps bispécifiques contre du CD3epsilon et BCMA pour utilisation dans le traitement de maladies |
PT3628687T (pt) | 2014-12-12 | 2021-10-20 | Bluebird Bio Inc | Recetores do antigénio quimérico bcma |
WO2016126608A1 (fr) | 2015-02-02 | 2016-08-11 | Novartis Ag | Cellules exprimant car dirigées contre de multiples antigènes tumoraux et leurs utilisations |
DK3283106T3 (da) * | 2015-04-13 | 2022-01-10 | Pfizer | Terapeutiske antistoffer og anvendelser deraf |
BR112017019914A2 (pt) * | 2015-04-13 | 2018-06-19 | Pfizer | receptores de antígenos quiméricos direcionados para antígeno de amadurecimento de células b |
EP3286211A1 (fr) | 2015-04-23 | 2018-02-28 | Novartis AG | Traitement du cancer à l'aide de protéine récepteur antigénique chimérique et un inhibiteur de protéine kinase |
EA036975B1 (ru) * | 2015-08-03 | 2021-01-21 | Энгмаб Сарл | Моноклональные антитела против bcma |
WO2017027392A1 (fr) | 2015-08-07 | 2017-02-16 | Novartis Ag | Traitement du cancer à l'aide des protéines de récepteur cd3 chimères |
JP2019501369A (ja) * | 2015-10-30 | 2019-01-17 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | 予後法 |
US10925969B2 (en) | 2015-11-13 | 2021-02-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Service | Anti-BCMA polypeptides and proteins |
WO2017091786A1 (fr) | 2015-11-23 | 2017-06-01 | Novartis Ag | Vecteurs de transfert lentiviral optimisés et utilisations associées |
JP6976943B2 (ja) | 2015-11-24 | 2021-12-08 | アネクソン,インコーポレーテッド | 抗補体因子C1q Fab断片及びその使用 |
PT3380522T (pt) * | 2015-11-25 | 2024-02-14 | Visterra Inc | Moléculas de anticorpos contra april e suas utilizações |
US20190256608A1 (en) * | 2015-12-01 | 2019-08-22 | Glaxosmithkline Intellectual Property Development Limited | Combination treatments and uses and methods thereof |
WO2017099712A1 (fr) | 2015-12-07 | 2017-06-15 | Bluebird Bio, Inc. | Compositions de lymphocytes t améliorées |
CN109072195A (zh) | 2015-12-30 | 2018-12-21 | 诺华股份有限公司 | 具有增强功效的免疫效应细胞疗法 |
US11698369B2 (en) | 2016-01-12 | 2023-07-11 | Oncotracker, Inc. | Methods for monitoring immune status of a subject |
SG11201806261XA (en) * | 2016-02-17 | 2018-09-27 | Seattle Genetics Inc | Bcma antibodies and use of same to treat cancer and immunological disorders |
US20200281973A1 (en) | 2016-03-04 | 2020-09-10 | Novartis Ag | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore |
WO2017165683A1 (fr) | 2016-03-23 | 2017-09-28 | Novartis Ag | Mini-corps sécrétés par des cellules et leurs usages |
CN117903307A (zh) * | 2016-04-01 | 2024-04-19 | 凯德药业股份有限公司 | Bcma结合分子及其使用方法 |
CN109328074A (zh) | 2016-04-01 | 2019-02-12 | 凯德药业股份有限公司 | 嵌合抗原和t细胞受体及使用的方法 |
CR20210084A (es) | 2016-04-01 | 2021-03-26 | Amgen Inc | Receptores quiméricos y métodos de uso de los mismos (divisional 2018-0480) |
KR20180134385A (ko) | 2016-04-15 | 2018-12-18 | 노파르티스 아게 | 선택적 단백질 발현을 위한 조성물 및 방법 |
JP7101621B2 (ja) | 2016-05-20 | 2022-07-15 | ハープーン セラピューティクス,インク. | 単一ドメイン血清アルブミン結合タンパク質 |
US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
IL299221A (en) | 2016-06-21 | 2023-02-01 | Teneobio Inc | CD3 binding antibodies |
EP3490590A2 (fr) | 2016-08-01 | 2019-06-05 | Novartis AG | Traitement du cancer au moyen d'un récepteur d'antigène chimérique en combinaison avec un inhibiteur d'une molécule de macrophage pro-m2 |
JP7030109B2 (ja) | 2016-09-14 | 2022-03-04 | テネオバイオ, インコーポレイテッド | Cd3結合抗体 |
JP7088932B2 (ja) * | 2016-09-14 | 2022-06-21 | ヤンセン バイオテツク,インコーポレーテツド | Bcma特異的フィブロネクチンiii型ドメインを有するキメラ抗原受容体、及びその使用 |
EP4295918A3 (fr) | 2016-11-02 | 2024-03-20 | Bristol-Myers Squibb Company | Anticorps bispécifiques contre bcma et cd3 et médicament dans le traitement du myélome multiple |
WO2018111340A1 (fr) | 2016-12-16 | 2018-06-21 | Novartis Ag | Procédés de détermination de la puissance et de la fonction proliférative de lymphocytes t à récepteur antigénique chimérique (car) |
EP4215548A1 (fr) * | 2016-12-21 | 2023-07-26 | Teneobio, Inc. | Anticorps uniquement à chaîne lourde anti-bcma |
CN108341872B (zh) * | 2017-01-23 | 2020-05-19 | 科济生物医药(上海)有限公司 | 靶向bcma的抗体及其应用 |
EP4043485A1 (fr) | 2017-01-26 | 2022-08-17 | Novartis AG | Compositions de cd28 et procédés pour une thérapie à base de récepteur antigénique chimérique |
JP2020506700A (ja) | 2017-01-31 | 2020-03-05 | ノバルティス アーゲー | 多重特異性を有するキメラt細胞受容体タンパク質を用いた癌の治療 |
CN110461335A (zh) | 2017-02-17 | 2019-11-15 | 弗雷德哈钦森癌症研究中心 | 用于治疗bcma相关癌症和自身免疫性失调的联合疗法 |
WO2018160731A1 (fr) | 2017-02-28 | 2018-09-07 | Novartis Ag | Compositions d'inhibiteur shp et utilisations pour une thérapie de récepteur d'antigène chimère |
JP7115758B2 (ja) | 2017-02-28 | 2022-08-09 | アッフィメッド・ゲー・エム・ベー・ハー | Cd16a指向性nk細胞エンゲージメント用タンデムダイアボディ |
US11535668B2 (en) | 2017-02-28 | 2022-12-27 | Harpoon Therapeutics, Inc. | Inducible monovalent antigen binding protein |
CN108624549B (zh) * | 2017-03-23 | 2020-11-20 | 上海奥浦迈生物科技有限公司 | 一种cho dg44培养基及其应用 |
EP3615068A1 (fr) | 2017-04-28 | 2020-03-04 | Novartis AG | Agent ciblant le bcma et polythérapie incluant un inhibiteur de gamma-sécrétase |
US20200055948A1 (en) | 2017-04-28 | 2020-02-20 | Novartis Ag | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
US11622977B2 (en) | 2017-05-12 | 2023-04-11 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
US11166985B2 (en) | 2017-05-12 | 2021-11-09 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
BR112019023855B1 (pt) | 2017-05-12 | 2021-11-30 | Harpoon Therapeutics, Inc | Proteínas de ligação à mesotelina |
EP3639028A4 (fr) | 2017-06-13 | 2021-04-14 | Inc. Onco Tracker | Méthodes de diagnostic, de pronostic et de surveillance de cancers à tumeur solide |
JP2020523383A (ja) | 2017-06-14 | 2020-08-06 | ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド | B細胞成熟抗原(bcma)指向性ナノ粒子 |
WO2018229715A1 (fr) | 2017-06-16 | 2018-12-20 | Novartis Ag | Compositions comprenant des anticorps anti-cd32b et procédés d'utilisation correspondants |
AU2018288803A1 (en) | 2017-06-20 | 2020-02-06 | Teneoone, Inc. | Anti-BCMA heavy chain-only antibodies |
EP3642237A2 (fr) | 2017-06-20 | 2020-04-29 | Teneobio, Inc. | Anticorps à chaîne lourde uniquement anti-bcma |
AU2018311503C1 (en) | 2017-08-01 | 2023-11-30 | Medimmune, Llc | BCMA monoclonal antibody-drug conjugate |
EP3694878A1 (fr) * | 2017-09-14 | 2020-08-19 | GlaxoSmithKline Intellectual Property Development Limited | Polythérapie pour le traitement du cancer |
EP3692066A2 (fr) | 2017-09-14 | 2020-08-12 | GlaxoSmithKline Intellectual Property Development Limited | Polythérapie pour le traitement du cancer |
CN111107874A (zh) * | 2017-09-14 | 2020-05-05 | 葛兰素史密斯克莱知识产权发展有限公司 | 用于癌症的组合治疗 |
EP3689908A4 (fr) * | 2017-09-29 | 2021-09-29 | Mogam Institute for Biomedical Research | Anticorps anti-bcma ayant une affinité élevée pour bcma et composition pharmaceutique pour le traitement du cancer, comprenant celui-ci |
CA3078637A1 (fr) | 2017-10-12 | 2019-04-18 | Mcmaster University | Coupleur d'antigenes de lymphocytes t a mutation y182t et procedes et utilisations de celui-ci |
AU2018346955A1 (en) | 2017-10-13 | 2020-04-30 | Harpoon Therapeutics, Inc. | B cell maturation antigen binding proteins |
CN111630070A (zh) | 2017-10-13 | 2020-09-04 | 哈普恩治疗公司 | 三特异性蛋白质及使用方法 |
KR20200086278A (ko) | 2017-10-18 | 2020-07-16 | 노파르티스 아게 | 선택적 단백질 분해를 위한 조성물 및 방법 |
WO2019081983A1 (fr) | 2017-10-25 | 2019-05-02 | Novartis Ag | Anticorps ciblant cd32b et leurs procédés d'utilisation |
WO2019089798A1 (fr) | 2017-10-31 | 2019-05-09 | Novartis Ag | Compositions anti-car et procédés |
AU2018360800A1 (en) | 2017-11-01 | 2020-05-14 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for B-cell maturation antigen (BCMA) |
GB201720426D0 (en) * | 2017-12-07 | 2018-01-24 | Hummingbird Bioscience Pte Ltd | CD47 and BCMA antigen-binding molecules |
BR112020008323A2 (pt) | 2017-11-01 | 2020-11-03 | Juno Therapeutics Inc | anticorpos e receptores de antígenos quiméricos específicos para antígeno de maturação de células b |
JP2021500926A (ja) | 2017-11-01 | 2021-01-14 | ハミングバード・バイオサイエンス・ホールディングス・プライベート・リミテッド | Cd47抗原結合分子 |
JP2021502979A (ja) | 2017-11-15 | 2021-02-04 | ノバルティス アーゲー | Bcmaターゲティングキメラ抗原受容体、cd19ターゲティングキメラ抗原受容体及び併用療法 |
TW201925782A (zh) | 2017-11-30 | 2019-07-01 | 瑞士商諾華公司 | 靶向bcma之嵌合抗原受體及其用途 |
WO2019133799A1 (fr) * | 2017-12-29 | 2019-07-04 | University Of Florida Research Foundation | Anticorps monoclonaux ciblant le domaine de liaison aux microtubules de la protéine tau |
EP3737408A1 (fr) | 2018-01-08 | 2020-11-18 | Novartis AG | Arns renforçant le système immunitaire pour une combinaison avec une thérapie par récepteur d'antigène chimérique |
AU2019215031A1 (en) | 2018-01-31 | 2020-08-20 | Novartis Ag | Combination therapy using a chimeric antigen receptor |
AU2019214163B2 (en) * | 2018-02-01 | 2021-06-24 | Innovent Biologics (Suzhou) Co., Ltd. | Chimeric antigen receptor (CAR) binding to BCMA, and uses thereof |
AU2019214183B2 (en) | 2018-02-01 | 2022-04-07 | Innovent Biologics (Suzhou) Co., Ltd. | Fully human anti-B cell maturation antigen (BCMA) single chain variable fragment, and application thereof |
US20200399383A1 (en) | 2018-02-13 | 2020-12-24 | Novartis Ag | Chimeric antigen receptor therapy in combination with il-15r and il15 |
WO2019164891A1 (fr) | 2018-02-21 | 2019-08-29 | Celgene Corporation | Anticorps de liaison à bcma et leurs utilisations |
CN112204052A (zh) * | 2018-04-05 | 2021-01-08 | 诺华股份有限公司 | 针对癌症的三特异性结合分子及其用途 |
CN116836297A (zh) * | 2018-04-12 | 2023-10-03 | 上海赛比曼生物科技有限公司 | 靶向bcma的嵌合抗原受体及其制法和应用 |
CN113817066A (zh) | 2018-04-13 | 2021-12-21 | 艾菲默德有限责任公司 | 自然杀伤细胞接合抗体融合构建体 |
US20210047405A1 (en) | 2018-04-27 | 2021-02-18 | Novartis Ag | Car t cell therapies with enhanced efficacy |
EP3788369A1 (fr) | 2018-05-01 | 2021-03-10 | Novartis Ag | Biomarqueurs pour évaluer des cellules car-t pour prédire un résultat clinique |
US20210060072A1 (en) | 2018-05-11 | 2021-03-04 | Crispr Therapeutics Ag | Methods and compositions for treating cancer |
US20210213063A1 (en) | 2018-05-25 | 2021-07-15 | Novartis Ag | Combination therapy with chimeric antigen receptor (car) therapies |
JP7398396B2 (ja) | 2018-06-01 | 2023-12-14 | ノバルティス アーゲー | Bcmaに対する結合分子及びその使用 |
EP3802825A1 (fr) | 2018-06-08 | 2021-04-14 | Intellia Therapeutics, Inc. | Compositions et procédés d'immuno-oncologie |
AU2019284911A1 (en) | 2018-06-13 | 2020-12-17 | Novartis Ag | BCMA chimeric antigen receptors and uses thereof |
AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
US11110123B2 (en) | 2018-07-17 | 2021-09-07 | Triumvira Immunologics Usa, Inc. | T cell-antigen coupler with various construct optimizations |
TWI838389B (zh) | 2018-07-19 | 2024-04-11 | 美商再生元醫藥公司 | 雙特異性抗-BCMAx抗-CD3抗體及其用途 |
EP3844265A2 (fr) | 2018-08-31 | 2021-07-07 | Novartis AG | Procédés de fabrication de cellules exprimant un récepteur d'antigène chimère |
SG11202101825QA (en) | 2018-08-31 | 2021-03-30 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
CA3114038A1 (fr) | 2018-09-25 | 2020-04-02 | Harpoon Therapeutics, Inc. | Proteines de liaison a dll3 et methodes d'utilisation |
KR20210068408A (ko) * | 2018-09-28 | 2021-06-09 | 암젠 인크 | 가용성 bcma에 대한 항체 |
US20210332145A1 (en) * | 2018-10-09 | 2021-10-28 | Single Cell Technology, Inc. | Anti-bcma antibodies |
CA3118191A1 (fr) | 2018-10-31 | 2020-05-07 | Glaxosmithkline Intellectual Property Development Limited | Procedes de traitement du cancer |
JP7410143B2 (ja) * | 2018-11-01 | 2024-01-09 | 山▲東▼新▲時▼代▲薬▼▲業▼有限公司 | 二重特異性抗体及びその用途 |
BR112021011874A2 (pt) | 2018-12-20 | 2021-09-08 | Novartis Ag | Regime de dosagem e combinação farmacêutica compreendendo derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona |
CN113924317A (zh) * | 2019-02-01 | 2022-01-11 | 葛兰素史克知识产权开发有限公司 | 贝兰他单抗莫福汀与派姆单抗组合用于治疗癌症 |
CN113329792B (zh) | 2019-02-15 | 2024-06-28 | 诺华股份有限公司 | 取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 |
CN113490528A (zh) | 2019-02-15 | 2021-10-08 | 诺华股份有限公司 | 3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 |
SG11202107825WA (en) | 2019-02-25 | 2021-09-29 | Novartis Ag | Mesoporous silica particles compositions for viral delivery |
EP3942025A1 (fr) | 2019-03-21 | 2022-01-26 | Novartis AG | Thérapies par cellules car-t à efficacité améliorée |
US20220168389A1 (en) | 2019-04-12 | 2022-06-02 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
EP3959320A1 (fr) | 2019-04-24 | 2022-03-02 | Novartis AG | Compositions et procédés de dégradation sélective de protéines |
EP3962535A1 (fr) | 2019-04-30 | 2022-03-09 | CRISPR Therapeutics AG | Thérapie cellulaire allogénique de malignités de lymphocytes b à l'aide de lymphocytes t génétiquement modifiés ciblant cd19 |
US20230081720A1 (en) | 2019-05-20 | 2023-03-16 | Novartis Ag | Mcl-1 inhibitor antibody-drug conjugates and methods of use |
US20220211861A1 (en) * | 2019-05-22 | 2022-07-07 | The Board of Trustees of the Leland Staford Junior University | Drug conjugates and methods of using same |
JP2022534969A (ja) * | 2019-05-31 | 2022-08-04 | メディミューン,エルエルシー | 併用療法 |
CA3140816A1 (fr) | 2019-06-14 | 2020-12-17 | Nathan Trinklein | Anticorps a chaines lourdes multispecifiques se liant a cd22 et cd3 |
US20220251228A1 (en) | 2019-07-30 | 2022-08-11 | Shanghai Hansoh Biomedical Co., Ltd. | Anti-bcma antibody, antigen-binding fragment thereof and medical use thereof |
KR20220041915A (ko) | 2019-08-06 | 2022-04-01 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 바이오제약 조성물 및 관련 방법 |
CN112409482B (zh) * | 2019-08-20 | 2022-08-26 | 杭州尚健生物技术有限公司 | Bcma抗体 |
CN112646032A (zh) * | 2019-10-10 | 2021-04-13 | 苏州亲为药业有限公司 | 靶向bcma的具有人猴交叉的人源化单克隆抗体 |
BR112022010206A2 (pt) | 2019-11-26 | 2022-11-29 | Novartis Ag | Receptores de antígeno quiméricos e usos dos mesmos |
CN114728065A (zh) * | 2019-11-26 | 2022-07-08 | 上海岸迈生物科技有限公司 | 针对cd3和bcma的抗体和自其制备的双特异性结合蛋白 |
CA3165399A1 (fr) | 2019-12-20 | 2021-06-24 | Novartis Ag | Utilisations d'anticorps anti-tgf-betas et inhibiteurs de point de controle pour le traitement des maladies proliferatives |
EP4085076A4 (fr) * | 2020-01-03 | 2024-01-24 | Biosion, Inc. | Anticorps se liant à bcma et leurs utilisations |
KR20220012314A (ko) * | 2020-01-03 | 2022-02-03 | 살루브리스 (청두) 바이오테크 코., 리미티드 | Bcma에 결합하는 항체 및 그의 용도 |
CN111234020B (zh) * | 2020-01-23 | 2020-10-23 | 和铂医药(苏州)有限公司 | 一种bcma结合蛋白及其制备方法和应用 |
CN115038466A (zh) | 2020-01-28 | 2022-09-09 | 葛兰素史密斯克莱知识产权发展有限公司 | 联合治疗及其用途和方法 |
CN113248611A (zh) * | 2020-02-13 | 2021-08-13 | 湖南华康恒健生物技术有限公司 | 抗bcma抗体、其药物组合物及应用 |
WO2021173985A2 (fr) | 2020-02-27 | 2021-09-02 | Novartis Ag | Méthodes de production de cellules exprimant un récepteur antigénique chimérique |
CN115397460A (zh) | 2020-02-27 | 2022-11-25 | 诺华股份有限公司 | 制备表达嵌合抗原受体的细胞的方法 |
BR112022022800A2 (pt) | 2020-05-11 | 2022-12-13 | Janssen Biotech Inc | Métodos para tratamento de mieloma múltiplo |
US20230332104A1 (en) | 2020-06-11 | 2023-10-19 | Novartis Ag | Zbtb32 inhibitors and uses thereof |
CN115850484A (zh) * | 2020-06-18 | 2023-03-28 | 重庆精准生物技术有限公司 | 一种靶向cd70的单链抗体及其应用 |
CA3182346A1 (fr) | 2020-06-23 | 2021-12-30 | Novartis Ag | Schema posologique comprenant des derives de 3-(1-oxoisoindoline-2-yl) piperidine-2,6-dione |
US20230271940A1 (en) | 2020-08-03 | 2023-08-31 | Novartis Ag | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
AU2021329404A1 (en) | 2020-08-21 | 2023-04-20 | Novartis Ag | Compositions and methods for in vivo generation of car expressing cells |
US20230374147A1 (en) | 2020-11-02 | 2023-11-23 | Hummingbird Bioscience Pte. Ltd. | Bcma/taci antigen-binding molecules |
CN116761635A (zh) | 2020-11-24 | 2023-09-15 | 诺华股份有限公司 | Bcl-xl抑制剂抗体药物缀合物及其使用方法 |
IL303473A (en) | 2020-12-31 | 2023-08-01 | Sana Biotechnology Inc | Methods and compositions for modulating CAR-T activity |
TW202246351A (zh) * | 2021-02-08 | 2022-12-01 | 美商恩格姆生物製藥公司 | Htra1結合劑及其使用方法 |
TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途 |
AU2022267891A1 (en) | 2021-04-27 | 2023-11-09 | Novartis Ag | Viral vector production system |
BR112023024231A2 (pt) | 2021-05-19 | 2024-01-30 | Sana Biotechnology Inc | Células t primárias rhd negativas hipoimunogênicas |
BR112023024434A2 (pt) | 2021-05-27 | 2024-02-20 | Sana Biotechnology Inc | Células hipoimunogênicas que compreendem hla-e ou hla-g geneticamente modificadas |
CA3220227A1 (fr) | 2021-05-28 | 2022-12-01 | Matthew Bruce | Polytherapies pour traiter le cancer |
AU2022283819A1 (en) | 2021-06-01 | 2024-01-04 | Triumvira Immunologics Usa, Inc. | Claudin 18.2 t cell-antigen couplers and uses thereof |
CN115521381A (zh) | 2021-06-24 | 2022-12-27 | 益科思特(北京)医药科技发展有限公司 | 结合bcma和cd3的双特异性抗体及其制备方法与应用 |
US11453723B1 (en) | 2021-06-25 | 2022-09-27 | Mcmaster University | BCMA T cell-antigen couplers and uses thereof |
AU2022301302A1 (en) | 2021-07-01 | 2024-01-25 | Indapta Therapeutics, Inc. | Engineered natural killer (nk) cells and related methods |
AU2022309875A1 (en) | 2021-07-14 | 2024-01-25 | Sana Biotechnology, Inc. | Altered expression of y chromosome-linked antigens in hypoimmunogenic cells |
TW202323822A (zh) | 2021-08-03 | 2023-06-16 | 英商葛蘭素史密斯克藍智慧財產發展有限公司 | 生藥組合物及穩定同位素標記肽之圖譜定位方法 |
EP4381081A1 (fr) | 2021-08-04 | 2024-06-12 | Sana Biotechnology, Inc. | Utilisation de vecteurs viraux ciblant cd4 |
AU2022327174A1 (en) | 2021-08-11 | 2024-02-15 | Sana Biotechnology, Inc. | Inducible systems for altering gene expression in hypoimmunogenic cells |
EP4388000A1 (fr) | 2021-08-20 | 2024-06-26 | Novartis AG | Procédés de fabrication de cellules exprimant un récepteur antigénique chimérique |
WO2023057893A1 (fr) | 2021-10-05 | 2023-04-13 | Glaxosmithkline Intellectual Property Development Limited | Polythérapies pour le traitement du cancer |
WO2023069790A1 (fr) | 2021-10-22 | 2023-04-27 | Sana Biotechnology, Inc. | Procédés de modification de lymphocytes t allogéniques avec un transgène dans un locus de tcr et compositions et procédés associés |
CA3236268A1 (fr) * | 2021-11-04 | 2023-05-11 | Jens G. LOHR | Mise au point de constructions de recepteurs antigeniques chimeriques en grappes (ccar) inductibles |
WO2023104138A1 (fr) * | 2021-12-09 | 2023-06-15 | 江苏先声药业有限公司 | Anticorps anti-bcma et son utilisation |
TW202342498A (zh) | 2021-12-17 | 2023-11-01 | 美商薩那生物科技公司 | 經修飾副黏液病毒科融合醣蛋白 |
TW202342757A (zh) | 2021-12-17 | 2023-11-01 | 美商薩那生物科技公司 | 經修飾副黏液病毒科附著醣蛋白 |
WO2023122337A1 (fr) | 2021-12-23 | 2023-06-29 | Sana Biotechnology, Inc. | Lymphocytes t à récepteur antigénique chimérique (car) pour le traitement d'une maladie auto-immune et méthodes associées |
WO2023133595A2 (fr) | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Méthodes de dosage et d'administration ex vivo de particules lipidiques ou de vecteurs viraux ainsi que systèmes et utilisations associés |
WO2023144702A1 (fr) | 2022-01-25 | 2023-08-03 | Glaxosmithkline Intellectual Property Development Limited | Polythérapie contre le cancer |
WO2023150518A1 (fr) | 2022-02-01 | 2023-08-10 | Sana Biotechnology, Inc. | Vecteurs lentiviraux ciblant cd3 et leurs utilisations |
WO2023150647A1 (fr) | 2022-02-02 | 2023-08-10 | Sana Biotechnology, Inc. | Procédés d'administration et de dosage répétés de particules lipidiques ou de vecteurs viraux et systèmes et utilisations connexes |
WO2023158836A1 (fr) | 2022-02-17 | 2023-08-24 | Sana Biotechnology, Inc. | Protéines cd47 modifiées et leurs utilisations |
WO2023178357A1 (fr) | 2022-03-18 | 2023-09-21 | Evolveimmune Therapeutics, Inc. | Molécules de fusion d'anticorps bispécifiques et leurs procédés d'utilisation |
WO2023193015A1 (fr) | 2022-04-01 | 2023-10-05 | Sana Biotechnology, Inc. | Polythérapies d'agoniste de récepteur de cytokine et de vecteur viral |
WO2023215725A1 (fr) | 2022-05-02 | 2023-11-09 | Fred Hutchinson Cancer Center | Compositions et méthodes pour l'immunothérapie cellulaire |
WO2023214325A1 (fr) | 2022-05-05 | 2023-11-09 | Novartis Ag | Dérivés de pyrazolopyrimidine et leurs utilisations en tant qu'inhibiteurs de tet2 |
WO2023232911A1 (fr) * | 2022-05-31 | 2023-12-07 | Oncopeptides Innovation 1 Ab | Nouveaux polypeptides |
WO2024007020A1 (fr) | 2022-06-30 | 2024-01-04 | Indapta Therapeutics, Inc. | Combinaison de cellules tueuses naturelles (nk) modifiées et d'une thérapie par anticorps et méthodes associées |
WO2024026377A1 (fr) | 2022-07-27 | 2024-02-01 | Sana Biotechnology, Inc. | Procédés de transduction utilisant un vecteur viral et des inhibiteurs de facteurs de restriction antiviraux |
WO2024064838A1 (fr) | 2022-09-21 | 2024-03-28 | Sana Biotechnology, Inc. | Particules lipidiques comprenant des glycoprotéines fixant des paramyxovirus variants et leurs utilisations |
WO2024081820A1 (fr) | 2022-10-13 | 2024-04-18 | Sana Biotechnology, Inc. | Particules virales ciblant des cellules souches hématopoïétiques |
WO2024089639A1 (fr) | 2022-10-26 | 2024-05-02 | Novartis Ag | Formulations lentivirales |
WO2024119157A1 (fr) | 2022-12-02 | 2024-06-06 | Sana Biotechnology, Inc. | Particules lipidiques avec cofusogènes et leurs procédés de production et d'utilisation |
WO2024121711A1 (fr) | 2022-12-05 | 2024-06-13 | Glaxosmithkline Intellectual Property Development Limited | Méthodes de traitement au moyen d'antagonistes d'antigène de maturation des lymphocytes b |
Family Cites Families (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3896111A (en) | 1973-02-20 | 1975-07-22 | Research Corp | Ansa macrolides |
US4151042A (en) | 1977-03-31 | 1979-04-24 | Takeda Chemical Industries, Ltd. | Method for producing maytansinol and its derivatives |
US4137230A (en) | 1977-11-14 | 1979-01-30 | Takeda Chemical Industries, Ltd. | Method for the production of maytansinoids |
US4265814A (en) | 1978-03-24 | 1981-05-05 | Takeda Chemical Industries | Matansinol 3-n-hexadecanoate |
US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
JPS5562090A (en) | 1978-10-27 | 1980-05-10 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
US4256746A (en) | 1978-11-14 | 1981-03-17 | Takeda Chemical Industries | Dechloromaytansinoids, their pharmaceutical compositions and method of use |
JPS55164687A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS5566585A (en) | 1978-11-14 | 1980-05-20 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS55102583A (en) | 1979-01-31 | 1980-08-05 | Takeda Chem Ind Ltd | 20-acyloxy-20-demethylmaytansinoid compound |
JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
JPS55164685A (en) | 1979-06-08 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS55164686A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
US4309428A (en) | 1979-07-30 | 1982-01-05 | Takeda Chemical Industries, Ltd. | Maytansinoids |
JPS5645483A (en) | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
JPS5645485A (en) | 1979-09-21 | 1981-04-25 | Takeda Chem Ind Ltd | Production of c-15003pnd |
EP0028683A1 (fr) | 1979-09-21 | 1981-05-20 | Takeda Chemical Industries, Ltd. | Antibiotique C-15003 PHO et sa préparation |
WO1982001188A1 (fr) | 1980-10-08 | 1982-04-15 | Takeda Chemical Industries Ltd | Composes 4,5-deoxymaytansinoide et leur procede de preparation |
US4450254A (en) | 1980-11-03 | 1984-05-22 | Standard Oil Company | Impact improvement of high nitrile resins |
JPS57106673A (en) | 1980-12-24 | 1982-07-02 | Chugai Pharmaceut Co Ltd | Dibenzo(b,f)(1,4)oxazepin derivative |
US4313946A (en) | 1981-01-27 | 1982-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids from Trewia nudiflora |
US4315929A (en) | 1981-01-27 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Method of controlling the European corn borer with trewiasine |
JPS57192389A (en) | 1981-05-20 | 1982-11-26 | Takeda Chem Ind Ltd | Novel maytansinoid |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US4880935A (en) | 1986-07-11 | 1989-11-14 | Icrf (Patents) Limited | Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates |
WO1988007089A1 (fr) | 1987-03-18 | 1988-09-22 | Medical Research Council | Anticorps alteres |
US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
US5770701A (en) | 1987-10-30 | 1998-06-23 | American Cyanamid Company | Process for preparing targeted forms of methyltrithio antitumor agents |
US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
US5053394A (en) | 1988-09-21 | 1991-10-01 | American Cyanamid Company | Targeted forms of methyltrithio antitumor agents |
IL106992A (en) | 1988-02-11 | 1994-06-24 | Bristol Myers Squibb Co | Noble hydrazonic history of anthracycline and methods for their preparation |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5362852A (en) | 1991-09-27 | 1994-11-08 | Pfizer Inc. | Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties |
US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
GB9424449D0 (en) | 1994-12-02 | 1995-01-18 | Wellcome Found | Antibodies |
US5663149A (en) | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
WO1997023243A1 (fr) | 1995-12-22 | 1997-07-03 | Bristol-Myers Squibb Company | Segments de liaison hydrazone ramifies |
DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
GB9809839D0 (en) | 1998-05-09 | 1998-07-08 | Glaxo Group Ltd | Antibody |
IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
US7115396B2 (en) | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
CA2704600C (fr) | 1999-04-09 | 2016-10-25 | Kyowa Hakko Kirin Co., Ltd. | Methode de production d'anticorps avec activite adcc accrue |
CN101371923B (zh) * | 1999-08-17 | 2013-04-17 | 比奥根艾迪克Ma公司 | Baff受体(bcma),一种免疫调节剂 |
MXPA02001665A (es) * | 1999-08-17 | 2003-07-14 | Biogen Inc | Receptor de baff (bcma) como agente inmunorregulador. |
JP4668498B2 (ja) | 1999-10-19 | 2011-04-13 | 協和発酵キリン株式会社 | ポリペプチドの製造方法 |
US6573074B2 (en) | 2000-04-12 | 2003-06-03 | Smithkline Beecham Plc | Methods for ansamitocin production |
WO2002020565A2 (fr) | 2000-09-08 | 2002-03-14 | Universität Zürich | Groupes de proteines a domaines de repetition comprenant des modules de repetition |
AR030612A1 (es) | 2000-09-12 | 2003-08-27 | Smithkline Beecham Corp | Procedimiento e intermedios |
US6374470B1 (en) | 2000-10-06 | 2002-04-23 | Milliken & Company | Face plate for spun-like textured yarn |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
AU2002220265A1 (en) * | 2000-11-03 | 2002-05-15 | University Of Vermont And State Agricultural College | Compositions for inhibiting grb7 |
WO2002066516A2 (fr) * | 2001-02-20 | 2002-08-29 | Zymogenetics, Inc. | Anticorps liant a la fois bcma et taci |
US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
US7256257B2 (en) | 2001-04-30 | 2007-08-14 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
CA2838062C (fr) | 2001-08-03 | 2015-12-22 | Roche Glycart Ag | Variants de glycosylation d'anticorps presentant une cytotoxicite cellulaire accrue dependante des anticorps |
EP1419179B1 (fr) | 2001-08-10 | 2010-03-03 | Aberdeen University | Domaines de liaison d'antigenes issus de poissons |
US7091186B2 (en) | 2001-09-24 | 2006-08-15 | Seattle Genetics, Inc. | p-Amidobenzylethers in drug delivery agents |
US20080267965A1 (en) | 2002-02-21 | 2008-10-30 | Kalled Susan L | Use of Bcma as an Immunoregulatory Agent |
AU2003263964C1 (en) | 2002-07-31 | 2010-08-19 | Seagen Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
EP1391213A1 (fr) | 2002-08-21 | 2004-02-25 | Boehringer Ingelheim International GmbH | Compositions et méthodes pour le traitement du cancer en utilisant un conjugué d'un anticorps contre le CD44 avec un maytansinoide et des agents chimiothérapeutiques |
EP1641818B1 (fr) | 2003-07-04 | 2008-12-03 | Affibody AB | Polypeptides presentant une affinite de liaison pour le recepteur 2 du facteur de croissance epidermique humain (her2) |
AU2003275958A1 (en) | 2003-08-25 | 2005-03-10 | Pieris Proteolab Ag | Muteins of tear lipocalin |
SI1725249T1 (sl) | 2003-11-06 | 2014-04-30 | Seattle Genetics, Inc. | Spojine monometilvalina, sposobne konjugacije na ligande |
KR20060129246A (ko) | 2003-12-05 | 2006-12-15 | 컴파운드 쎄라퓨틱스, 인크. | 타입 2 혈관 내피 성장 인자 수용체의 억제제 |
WO2005075511A1 (fr) * | 2004-01-29 | 2005-08-18 | Genentech, Inc. | Variants du domaine extracellulaire de bcma et utilisations de ceux-ci |
EP1776385A1 (fr) | 2004-07-21 | 2007-04-25 | Glycofi, Inc. | Immunoglobulines contenant principalement un glycoforme de type glcnac2man3glcnac2 |
WO2006067210A1 (fr) * | 2004-12-23 | 2006-06-29 | Laboratoires Serono S.A. | Polypeptides bcma et leurs utilisations |
AU2006270718B2 (en) | 2005-07-22 | 2011-07-21 | Kyowa Kirin Co., Ltd. | Genetically modified antibody composition |
US7923538B2 (en) | 2005-07-22 | 2011-04-12 | Kyowa Hakko Kirin Co., Ltd | Recombinant antibody composition |
MX2008015882A (es) * | 2006-06-22 | 2009-01-12 | Genentech Inc | Metodos y composiciones para hacer blanco en hepsina. |
CA2661872A1 (fr) * | 2006-08-28 | 2008-03-06 | Ares Trading S.A. | Procede de purification de proteines fc-hybrides |
EP1958957A1 (fr) | 2007-02-16 | 2008-08-20 | NascaCell Technologies AG | Polypeptide comprenant un partie caractéristique des protéines appellées "Knottins" |
WO2009090032A1 (fr) * | 2008-01-15 | 2009-07-23 | F. Hoffmann-La Roche Ag | Anticorps afucosylés contre ccr5 et leurs utilisations |
ES2593583T3 (es) * | 2009-03-10 | 2016-12-09 | Biogen Ma Inc. | Anticuerpos anti-BCMA |
WO2011108008A2 (fr) * | 2010-03-04 | 2011-09-09 | Transgene Biotek Ltd. | Anticorps tbl-cln1 pour une élimination de cellules cancéreuses par induction ciblée d'apoptose, de cdc (cytotoxicité dépendante du complément) et d'adcc (cytotoxicité cellulaire dépendante des anticorps) |
US20130273055A1 (en) * | 2010-11-16 | 2013-10-17 | Eric Borges | Agents and methods for treating diseases that correlate with bcma expression |
DK3415531T3 (da) | 2011-05-27 | 2023-09-18 | Glaxo Group Ltd | Bcma (cd269/tnfrsf17)-bindende proteiner |
UA112434C2 (uk) * | 2011-05-27 | 2016-09-12 | Ґлаксо Ґруп Лімітед | Антигензв'язувальний білок, який специфічно зв'язується з всма |
-
2012
- 2012-05-24 DK DK18163942.8T patent/DK3415531T3/da active
- 2012-05-24 ES ES18163942T patent/ES2953190T3/es active Active
- 2012-05-24 PL PL18163942.8T patent/PL3415531T3/pl unknown
- 2012-05-24 PE PE2013002545A patent/PE20141045A1/es active IP Right Grant
- 2012-05-24 WO PCT/EP2012/059762 patent/WO2012163805A1/fr active Application Filing
- 2012-05-24 AU AU2012264890A patent/AU2012264890C1/en active Active
- 2012-05-24 MX MX2013013942A patent/MX351069B/es active IP Right Grant
- 2012-05-24 EA EA201391457A patent/EA028220B1/ru not_active IP Right Cessation
- 2012-05-24 MY MYPI2013702251A patent/MY177970A/en unknown
- 2012-05-24 BR BR112013028779A patent/BR112013028779B8/pt active IP Right Grant
- 2012-05-24 EP EP20153215.7A patent/EP3693394A1/fr not_active Withdrawn
- 2012-05-24 PT PT181639428T patent/PT3415531T/pt unknown
- 2012-05-24 RS RS20231039A patent/RS64791B1/sr unknown
- 2012-05-24 HU HUE18163942A patent/HUE063461T2/hu unknown
- 2012-05-24 KR KR1020137034803A patent/KR101972446B1/ko active IP Right Grant
- 2012-05-24 LT LTEP18163942.8T patent/LT3415531T/lt unknown
- 2012-05-24 US US14/122,391 patent/US20140105915A1/en not_active Abandoned
- 2012-05-24 EP EP23183917.6A patent/EP4338754A3/fr active Pending
- 2012-05-24 CA CA2833820A patent/CA2833820C/fr active Active
- 2012-05-24 HR HRP20231066TT patent/HRP20231066T1/hr unknown
- 2012-05-24 EP EP18163942.8A patent/EP3415531B1/fr active Active
- 2012-05-24 EA EA201790330A patent/EA201790330A1/ru unknown
- 2012-05-24 CN CN201610808775.0A patent/CN106279418A/zh active Pending
- 2012-05-24 CN CN201280025793.1A patent/CN103562225B/zh active Active
- 2012-05-24 SG SG2013076138A patent/SG194176A1/en unknown
- 2012-05-24 EP EP12723206.4A patent/EP2714737A1/fr not_active Withdrawn
- 2012-05-24 SI SI201232040T patent/SI3415531T1/sl unknown
- 2012-05-24 JP JP2014511888A patent/JP6263467B2/ja active Active
- 2012-05-24 FI FIEP18163942.8T patent/FI3415531T3/fi active
- 2012-05-25 TW TW106128318A patent/TWI644924B/zh active
- 2012-05-25 UY UY0001034101A patent/UY34101A/es not_active Application Discontinuation
- 2012-05-25 TW TW101118855A patent/TWI609883B/zh active
- 2012-05-28 AR ARP120101871A patent/AR086579A1/es active IP Right Grant
-
2013
- 2013-10-08 IL IL228784A patent/IL228784B/en active IP Right Grant
- 2013-11-18 ZA ZA2013/08635A patent/ZA201308635B/en unknown
- 2013-11-19 CO CO13271946A patent/CO6811809A2/es active IP Right Grant
- 2013-11-25 CL CL2013003373A patent/CL2013003373A1/es unknown
- 2013-11-26 DO DO2013000280A patent/DOP2013000280A/es unknown
- 2013-11-27 CR CR20130624A patent/CR20130624A/es unknown
- 2013-12-25 MA MA36613A patent/MA35208B1/fr unknown
-
2016
- 2016-10-12 CL CL2016002585A patent/CL2016002585A1/es unknown
-
2017
- 2017-10-25 IL IL255253A patent/IL255253A0/en unknown
- 2017-12-18 JP JP2017241606A patent/JP2018087190A/ja active Pending
-
2019
- 2019-04-22 JP JP2019080646A patent/JP7018910B2/ja active Active
-
2021
- 2021-11-19 JP JP2021188586A patent/JP7260621B2/ja active Active
-
2023
- 2023-04-06 JP JP2023062129A patent/JP7475515B2/ja active Active
- 2023-09-07 CY CY20231100477T patent/CY1126300T1/el unknown
- 2023-09-07 CY CY2023019C patent/CY2023019I1/el unknown
- 2023-09-07 FR FR23C1032C patent/FR23C1032I1/fr active Active
- 2023-09-07 FI FIC20230029C patent/FIC20230029I1/fi unknown
- 2023-09-07 NL NL301241C patent/NL301241I2/nl unknown
- 2023-10-27 HU HUS2300027C patent/HUS2300027I1/hu unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA35208B1 (fr) | Protéines de liaison à bcma (cd269/tnfrsf17) | |
EA201000424A1 (ru) | Антитела к il-23 | |
UA109633C2 (uk) | Антитіло людини проти тканинного фактора | |
CY1117942T1 (el) | Αντισωματα προσδεματος επαγωγης πολλαπλασιασμου (april) | |
UA112434C2 (uk) | Антигензв'язувальний білок, який специфічно зв'язується з всма | |
BR112012025568A2 (pt) | proteínas de ligação ao tnf-<244>. | |
UA116194C2 (uk) | Антитіло, яке специфічно зв'язується з людським альфа-синуклеїном | |
MA40041A (fr) | Anticorps anti-gitr et leurs procédés d'utilisation | |
EP2680004A3 (fr) | Compositions et procédés pour la détection du cancer | |
SG164369A1 (en) | Human anti-b7rp1 neutralizing antibodies | |
EP2987807A3 (fr) | Anticorps dirigés contre tau phosphorylée | |
EA201290849A1 (ru) | Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора (tfpi) | |
NO20054170L (no) | Antistoff mot human IL-21 reseptor og anvendelser derav | |
EA201100062A1 (ru) | Соединения и способы модулирования рецепторов, связанных с белком g | |
MX2009012950A (es) | ANTICUERPOS HUMANIZADOS CONTRA EL GLOBULOMERO Aß (20-42) Y SUS USOS. | |
TW200738748A (en) | Human monoclonal antibody human CD134 (OX40) and methods of making and using same | |
EA201170357A1 (ru) | Инженерные антитела к il-13: композиции, способы и применение | |
MA33387B1 (fr) | Polypeptides et procede de traitement | |
IL187321A (en) | Molecules that have a specific link to a surrogate cell that encode monoclonal antibodies capable of neutralizing viruses, medicinal preparations containing them, and their uses in drug preparation | |
TR201907261T4 (tr) | DKK-1 antikorları. | |
EA201070725A1 (ru) | Бис-пиридилпиридоны как антагонисты рецептора 1 меланинконцентрирующего гормона | |
MA34742B1 (fr) | Proteines de liaison à l'antigène | |
TH149802A (th) | โปรตีนจับเกาะแอนติเจน | |
TH158980A (th) | โปรตีนยึดเกาะ bcma (cd269/tnfrsf17) | |
UA98756C2 (ru) | Антитело, которое связывается с cd38, для лечения заболевания, опосредованного cd38 |